Daré Bioscience, Inc. DARE
0.43 USD -0.16 (-26.57%)
Regular-session close
0.44 +0.01 +1.66%
After hours · Nov 17, 7:30 PM ET
0.415 Day range 0.5882
0.415 52-week range 3.78
- YTD
- -77.77%
- 1 year
- -76.30%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) shares rose 169.8% to $20.16 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 billion. As per the press release,…
seekingalpha.com Daré Bioscience, Inc. (DARE) Q3 2026 Earnings Call Transcript Daré Bioscience, Inc. (DARE) Q3 2026 Earnings Call Transcript
zacks.com Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.28 per share a year ago.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Dare Bioscience (NASDAQ:DARE) shares rose 9.5% to $0.64 during Monday's after-market session. The company's market cap stands at $12.9 million. As per the press release, Q3 earnings came out…benzinga.com Dare Bioscience Q3 EPS $(0.18) Beats $(0.26) Estimate, Sales $47.628K Miss $2.018M Estimate Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.26) by 30.77 percent. This is a 35.71 percent increase over losses of…
globenewswire.com Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement DARE to PLAY™ Sildenafil Cream prescription dispensing activities underway this month, with prescriptions written across 48 states and Washington, D.C.
globenewswire.com Daré Bioscience Receives Approximately $852,000 in Additional Grant Funding Additional funding represents the second-to-last anticipated payment under the up to approximately $10.7 million grant agreement supporting preclinical development of a novel non-hormonal…
globenewswire.com Daré Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026 SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising…
globenewswire.com Daré Bioscience Releases Next Episode in “CEO Corner” Video Series Sabrina Martucci Johnson, Founder, President and CEO, discusses numerous potential value drivers expected to power the Company's next phase of growth and commercial success
globenewswire.com Daré Bioscience to Present at Stifel's 2026 Healthcare Conference SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…benzinga.com Daré Bioscience Receive Additional $1.5M Funding Installment Under Grant Agreement For DARE-LARC1 With this installment, Daré Bioscience has received a total of approximately $43.3 million in non-dilutive funding under the grant agreement. The remaining approximately $5.6 million of the up to…
globenewswire.com Daré Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum Latest $1.5 Million Installment Reflects Continued Milestone Progress as DARE-LARC1 Advances in Preclinical Development
globenewswire.com Daré Bioscience Addresses New National Focus on Women's Health in Virtual Investor “What This Means” Discussion Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience's growing commercial portfolio and clinical pipeline position the…
globenewswire.com Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program
globenewswire.com Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer Premier sponsorship of the HERmedicine and OncoMenopause Consortium® program underscores Daré Bioscience's commitment to addressing unmet women's health needs, including for women affected by breast…
globenewswire.com Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience's growing commercial portfolio, clinical pipeline and…
defenseworld.net Contrasting RYTHM (NASDAQ:RYM) & Dare Bioscience (NASDAQ:DARE) Dare Bioscience (NASDAQ: DARE - Get Free Report) and RYTHM (NASDAQ: RYM - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two…
globenewswire.com Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection New U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection
globenewswire.com Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%
globenewswire.com Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand View the video webcast here
globenewswire.com Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
globenewswire.com Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series Video webcast now available here
seekingalpha.com Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
globenewswire.com Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities…
